Literature DB >> 43552

Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine.

M D Allen, D J Greenblatt, J D Arnold.   

Abstract

The pharmacokinetic properties of estazolam, a triazolo benzodiazepine hypnotic agent, were assessed in a series of healthy volunteers following single and multiple doses. After single oral doses of 2--16 mg, peak plasma concentrations were reached within 6 h. Values of elimination half-life ranged from 8.3--31.2 h (mean 17.0 h) and did not vary significantly with dose. During 3 weeks of therapy, steady-state plasma concentrations increased approximately in proportion to increasing doses. and accumulation was essentially complete within 3 days of each dose change. The mean observed accumulation ratio was 1.84, which was slightly larger than the predicted ratio of 1.53. Exposure to multiple-dose estazolam therapy had no significant influence on the kinetics of a single dose of antipyrine, suggesting that estazolam neither stimulates nor inhibits enzyme activity in humans. Thus the accumulation and elimination kinetics of estazolam can be classified as intermediate to those of the short-acting (such as oxazepam) and the long-acting (such as diazepam) benzodiazepine derivatives.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 43552     DOI: 10.1007/bf00428318

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  The estimation of antipyrine in biological materials.

Authors:  B B BRODIE; J AXELROD
Journal:  J Biol Chem       Date:  1949-05       Impact factor: 5.157

2.  Determination of desmethyldiazepam in plasma by electron-capture GLC: application to pharmacokinetic studies of clorazepate.

Authors:  D J Greenblatt
Journal:  J Pharm Sci       Date:  1978-03       Impact factor: 3.534

3.  Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam.

Authors:  D J Greenblatt; K Franke; R I Shader
Journal:  J Chromatogr       Date:  1978-09-01

4.  Pharmacokinetic understanding of antianxiety drug therapy.

Authors:  D J Greenblatt; R I Shader
Journal:  South Med J       Date:  1978-08       Impact factor: 0.954

5.  Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.

Authors:  D J Greenblatt; R I Shader; K Franke; D S MacLaughlin; J S Harmatz; M D Allen; A Werner; E Woo
Journal:  J Pharm Sci       Date:  1979-01       Impact factor: 3.534

6.  Simultaneous gas-chromatographic analysis for diazepam and its major metabolite, desmethyldiazepam, with use of double internal standardization.

Authors:  D J Greenblatt
Journal:  Clin Chem       Date:  1978-10       Impact factor: 8.327

Review 7.  Predicting steady state serum concentrations of drugs.

Authors:  D J Greenblatt
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

8.  Effects of chronic prazepam administration on drug metabolism in man and rat.

Authors:  E S Vesell; G T Passananti; J P Viau; J E Epps; F J Di Carlo
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

9.  Determination of medazepam (nobrium), diazepam(valium) and their major biotransformation products in blod and urine by electron capture s-liquid chromatography.

Authors:  J A De Silva; C V Puglisi
Journal:  Anal Chem       Date:  1970-12       Impact factor: 6.986

10.  The biotransformation of 8-chloro-6-phenyl-4H-s-triazolo(4,3-a) (1,4) benzodiazepine (D-40TA), a new central depressant, in man, dog and rat.

Authors:  Y Kanai
Journal:  Xenobiotica       Date:  1974-07       Impact factor: 1.908

View more
  5 in total

Review 1.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

2.  Effects of estazolam as a premedication in mentally retarded patients.

Authors:  Yuichi Kanmura; Mutumi Kamihashi
Journal:  J Anesth       Date:  1997-03       Impact factor: 2.078

Review 3.  Pharmacological treatment of insomnia.

Authors:  M Maczaj
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

4.  Benzodiazepines: a summary of pharmacokinetic properties.

Authors:  D J Greenblatt; R I Shader; M Divoll; J S Harmatz
Journal:  Br J Clin Pharmacol       Date:  1981       Impact factor: 4.335

Review 5.  [Benzodiazepines: significance of kinetics for therapy].

Authors:  H R Ochs
Journal:  Klin Wochenschr       Date:  1983-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.